Apyx Medical (APYX)
(Delayed Data from NSDQ)
$1.50 USD
-0.16 (-9.64%)
Updated May 10, 2024 04:00 PM ET
After-Market: $1.50 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth C Momentum D VGM
Balance Sheet
Fiscal Year End for Apyx Medical Corporation falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 44 | 10 | 31 | 42 | 59 |
Receivables | 14 | 18 | 21 | 17 | 9 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 10 | 12 | 7 | 4 | 5 |
Other Current Assets | 3 | 3 | 2 | 3 | 4 |
Total Current Assets | 70 | 43 | 61 | 66 | 77 |
Net Property & Equipment | 2 | 7 | 7 | 7 | 7 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 1 | 1 | 1 | 0 |
Total Assets | 79 | 52 | 69 | 74 | 85 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 3 | 3 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 10 | 9 | 10 | 7 | 9 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 13 | 12 | 13 | 9 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 33 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 2 | 1 | 1 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 52 | 14 | 15 | 10 | 13 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 81 | 73 | 66 | 61 | 57 |
Retained Earnings | -54 | -36 | -13 | 3 | 15 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 27 | 38 | 54 | 64 | 71 |
Total Liabilities & Shareholder's Equity | 79 | 52 | 69 | 74 | 85 |
Total Common Equity | 27 | 38 | 54 | 64 | 71 |
Shares Outstanding | 34.60 | 34.60 | 34.30 | 34.20 | 34.10 |
Book Value Per Share | 0.78 | 1.09 | 1.57 | 1.87 | 2.09 |
Fiscal Year End for Apyx Medical Corporation falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 44 | 22 | 18 | 16 |
Receivables | NA | 14 | 13 | 20 | 18 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 10 | 11 | 11 | 11 |
Other Current Assets | NA | 3 | 3 | 3 | 7 |
Total Current Assets | NA | 70 | 50 | 53 | 53 |
Net Property & Equipment | NA | 2 | 2 | 2 | 2 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 2 | 2 | 2 | 1 |
Total Assets | NA | 79 | 59 | 62 | 57 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 3 | 2 | 3 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 9 | 9 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 10 | 8 | 7 | 8 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 13 | 10 | 19 | 19 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 33 | 9 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 2 | 2 | 2 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 52 | 26 | 26 | 21 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 81 | 78 | 77 | 75 |
Retained Earnings | NA | -54 | -45 | -40 | -39 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 27 | 34 | 37 | 36 |
Total Liabilities & Shareholder's Equity | NA | 79 | 59 | 62 | 57 |
Total Common Equity | 0 | 27 | 34 | 37 | 36 |
Shares Outstanding | 34.60 | 34.60 | 34.60 | 34.60 | 34.60 |
Book Value Per Share | 0.00 | 0.78 | 0.97 | 1.06 | 1.05 |